SRSF2 Antibody

1. mutations in myelodysplasia patients preferentially affect splicing at 3' splice sites rather than at 5' splice sites PMID: 30194306
2. SRSF2 mutations were significantly related to the shorter OS in patients with myelodysplastic syndromes which may consider as an adverse prognostic risk factor. Whereas, analysis did not show any prognostic effect on overall-survival of chronic myelomonocytic leukemia patients with SRSF2 mutations. PMID: 29757120
3. SRSF2 is highly expressed in hepatocellular carcinoma and its expression increases with the degree of tumor differentiation and TNM staging. It is related to lymph node metastasis and metastasis of tumor cells, and is positively related to serum alpha fetoprotein content, and affects the postoperative survival time of HCC patients. PMID: 29278882
4. We found that SON and SC35 (also known as SRSF2) localize to the central region of the speckle, whereas MALAT1 and small nuclear (sn)RNAs are enriched at the speckle periphery. PMID: 29133588
5. Through a serial mutagenesis, authors demonstrate that a 10 nt RNA sequence surrounding the branch-point (BP), is important for SRSF2-mediated inhibition of cassette exon inclusion through directly interacting with SRSF2. PMID: 28712387
6. The aberrantly spliced target genes and deregulated cellular pathways associated with the commonly mutated splicing factor genes in myelodysplastic syndromes (SF3B1, SRSF2 and U2AF1) are being identified, illuminating the molecular mechanisms underlying the disease. (Review) PMID: 27639445
7. adverse prognostic impact of SRSF2 mutations on OS and AML transformation in patients with de novo MDS PMID: 28953917
8. SRSF2 mutation is associated with chronic myelomonocytic leukemia. PMID: 28209919
9. Posttranslational modification of SR proteins underlies the regulation of their mRNA export activities and distinguishes pluripotent from differentiated cells. PMID: 28592444
10. Mutation in SRSF2 gene is associated with Uveal Melanoma. PMID: 28810145
11. Myelodysplastic syndrome -related P95 point mutants of SRSF2 lead to alternative splicing of CDC25C in a manner that is not dependent on the DNA damage response. PMID: 27552991
12. Findings identify SRSF2 as a key regulator of RNA splicing dysregulation in cancer, with possible clinical implications as a candidate prognostic factor in patients with HCC. PMID: 28082404
13. depletion of the splicing factor arginine-rich splicing factor 2 (SRSF2) leads to enhanced cytotoxicity of breast cancer cells by KM100 PMID: 26257065
14. Data suggest that RBM25 is required for the viability of multiple human cell lines, suggesting that it could play a key role in pre-mRNA splicing; a region of RBM25 spanning Lys77 binds with high affinity to SRSF2, a crucial protein in exon definition, but only when Lys77 is unmethylated. (RBM25 = RNA binding motif protein 25; SRSF2 = serine- and arginine-rich splicing factor 2) PMID: 28655759
15. mutations in the SRSF2/ASXL1/RUNX1 gene panel identified as significant prognostic markers in systemic mastocytosis PMID: 27416984
16. It was found that the absence of mutations in the SRSF2, ASXL1, and/or RUNX1gene panel at baseline and a reduction of the KIT D816V allele burden more than 25% at month 6 are the most favorable predictors for improved survival in midostaurin-treated advanced systemic mastocytosis patients. PMID: 28424161
17. These findings provide insight into the functions of SRSF2 in HSV-1 replication and gene expression. PMID: 27784784
18. SRSF2 mutations were identified in Chinese AML patients. Patients with SRSF2 mutations were older than those with wild-type. No differences in the sex, blood parameters, FAB subtypes, and karyotypes were seen between AML patients with and without SRSF2 mutations. SRSF2 mutation was not an independent prognostic factor in AML patients. PMID: 26820131
19. The genotype frequencies of SRSF2 SNP rs237057 were CT 7.6% and TT 92.4% in Childhood AML patients. PMID: 25553291
20. We present experimental evidence that splicing factor SRSF1, SRSF2, U2AF35, U2AF65 and KHSRP expression levels in gastrointestinal tract (colon, gastric and pancreatic) tumors differ compare to healthy tissues and in cell lines. PMID: 26406946
21. Data show that tet methylcytosine dioxygenase 2 TET2, isocitrate dehydrogenases 1/2 IDH1/IDH2, serine/arginine-rich splicing factor 2 SRSF2, splicing factor 3b subunit 1 SF3B1, and ras proteins (KRAS/NRAS) are not conserved in dog mast Cell tumors. PMID: 26562302
22. Depletion of two of the most potent inhibitors of SMP2 exon 7 inclusion, SRSF2 or SRSF3, in cell lines derived from SMA patients, increased SMN2 exon 7 inclusion and SMN protein level. PMID: 25506695
23. HIV-1-Tat Protein Inhibits SC35-mediated Tau Exon 10 Inclusion through Up-regulation of DYRK1A Kinase. PMID: 26534959
24. Our results show that diverse microenvironment cues affect different attributes of the SC-35 organizational metrics and lead to distinct emergent organizational patterns. PMID: 25765854
25. findings shed light on the mechanism of the disease-associated SRSF2 mutation in splicing regulation and also reveal a group of misspliced mRNA isoforms for potential therapeutic targeting PMID: 26261309
26. The authors propose that splicing at 3'ss A3 is dependent on binding of the enhancing SR proteins SRSF2 and SRSF6 to the HIV-1 tat ESE and ESE2 sequence. PMID: 25889056
27. clinical relevance of SRSF2 mutations in Chinese myelodysplastic syndrome PMID: 25541999
28. SRSF2 mutations are frequent in chronic myelomonocytic leukemia patients, but show a relatively lower incidence in Chinese patients. PMID: 25533824
29. SRSF2 splicing factor gene mutations diagnose myelodysplastic syndromes. PMID: 25445211
30. The mutational status of the SRSF2, U2AF1 and ZRSR2 did not affect the response rate or survival in MDS patients who had received first-line decitabine treatment. PMID: 25964599
31. SRSF2 is required for expression of HPV16 E6E7 mRNAs in cervical tumor but not nontumor cells and may act by inhibiting their decay. PMID: 25717103
32. Mutation in SRSF2 gene is associated with secondary acute myeloid leukemia. PMID: 25550361
33. acts in concert with OCT4 and miRNAs to mediate protein diversity via alternative splicing enforcing a state of pluripotency PMID: 24813856
34. SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes. PMID: 24389310
35. Molecular monitoring of patients having undergone AHSCT for PMF should not be restricted to JAK2, MPL or CALR, but all mutations present in primary fibrotic neoplastic myeloproliferation should be included to interpret abnormal blood values after AHSCT PMID: 25231745
36. The SRSF2 is a unique SR protein that activates transcription in a position-dependent manner while three other SR proteins enhance translation in a position-independent fashion. PMID: 24406341
37. SRSF2 mutations are frequent in chronic myelomonocytic leukemia and a useful diagnostic feature demonstrable in BM biopsies, allowing a definitive diagnosis for cases with minimal dysplasia and normal karyotype. PMID: 25305095
38. SRSF2 promotes exon 11 inclusion of Ron proto-oncogene through targeting exon 11. PMID: 25220236
39. Protein kinase A interacts with and phosphorylates SC35 and enhances SC35-promoted tau exon 10 inclusion. PMID: 24037441
40. SC35 promotes the production of the C5-V6-C6 isoform of CD44. Knockdown of SC35 reduces the expression of the CD44V6 isoform. PMID: 24173428
41. SETBP1 and SRSF2 are the most common somatic genetic abnormalities in patients with myeloid neoplasms carrying isochrmosome 17(q10), and may be important drivers of disease pathogenesis. PMID: 24796269
42. The SC35 exonic splicing enhancer motif is conserved within the same chromosome but not between different human chromosomes. PMID: 24792892
43. IDH mutations were closely associated with mutations of DNMT3A, ASXL1, and SRSF2, suggesting the interaction of IDH mutations with these gene aberrations may play a role in the development of MDS. PMID: 24115220
44. Data show that myelodysplastic chronic myelomonocytic leukemias are characterized by mutations in transcription/epigenetic regulators ASXL1, RUNX1, TET2 and SRSF2. PMID: 23065512
45. A new function of the splicing factor SRSF2 in the control of E2F1-mediated cell cycle progression in neuroendocrine lung tumors. PMID: 23518498
46. In primary myelofibrosis, SRSF2 mutation appears to be stable and not associated with progression from previous thrombocytosis to cytopenia. PMID: 23660863
47. data suggest that SF3B1, U2AF1 and SRSF2 mutations occur not only in myeloid lineage tumors but also in lymphoid lineage tumors; data suggest that the splicing gene mutations play important roles in the pathogenesis of hematologic tumors, but rarely in solid tumors PMID: 23280334
48. SRSF2 is the most frequently mutated spliceosome gene in chronic myelomonocytic leukemia, but neither it nor SF3B1 or U2AF35 mutations are prognostically relevant. PMID: 23335386
49. In 187 primary myelofibrosis patients, 17% had SRSF2 mutations at P95. They were associated with shorter survival. PMID: 22968464
50. SRSF2 mutations are associated with chronic myelomonocytic leukemia PMID: 22919025

Show More

Hide All

HGNC: 10783

OMIM: 600813

KEGG: hsa:6427

STRING: 9606.ENSP00000353089

UniGene: Hs.584801